CSMD2 and neoplasm: Immunohistochemistry (IHC) analysis of tumor biopsy samples confirmed a loss of CSMD2 and enhanced EXT1 expression in tumor and PVTT cells (Fig. 5a), whereas MED30 expression was unchanged (data not shown).